Search hospitals > North Carolina > Concord
Atrium Health Cabarrus/LCI-Concord
Claim this profileConcord, North Carolina 28025
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Adenocarcinoma
Conducts research for Recurrence
Conducts research for Lung Cancer
87 reported clinical trials
13 medical researchers
Summary
Atrium Health Cabarrus/LCI-Concord is a medical facility located in Concord, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Lung Cancer and other specialties. Atrium Health Cabarrus/LCI-Concord is involved with conducting 87 clinical trials across 165 conditions. There are 13 research doctors associated with this hospital, such as Nilanjan Ghosh, Earle Burgess, MD, Daniel R. Carrizosa, and John H. Heinzerling.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 positive
ER positive
HER2 negative
Top PIs
Nilanjan GhoshLevine Cancer Institute4 years of reported clinical research
Studies Lymphoma
Studies B-Cell Lymphoma
8 reported clinical trials
13 drugs studied
Earle Burgess, MDLevine Cancer Institute2 years of reported clinical research
Studies Prostate Cancer
Studies Cancer
6 reported clinical trials
26 drugs studied
Daniel R. CarrizosaLevine Cancer Institute-Rock Hill5 years of reported clinical research
Studies Non-Small Cell Lung Cancer
Studies Lung Cancer
5 reported clinical trials
12 drugs studied
John H. HeinzerlingCarolinas Medical Center/Levine Cancer Institute8 years of reported clinical research
Studies Lung Cancer
Studies Small Cell Lung Cancer
5 reported clinical trials
19 drugs studied
Clinical Trials running at Atrium Health Cabarrus/LCI-Concord
Breast Cancer
Prostate Cancer
Cancer
Lung Cancer
Squamous Cell Carcinoma
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
Small Intestinal Adenocarcinoma
Tumors
Anal Squamous Cell Carcinoma
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Hormone Therapy with or without Radiation
for Breast Cancer
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor recurrence (IBTR) compared to breast conservation with breast radiation and endocrine therapy.
Recruiting2 awards Phase 313 criteria
Single vs Multiple Dose Radiation
for Brain Metastases
This study is designed to see if we can lower the chance of side effects from radiation in patients with breast, kidney, small cell lung cancer, non-small cell lung cancer or melanoma that has spread to the brain and who are also being treated with immunotherapy, specifically immune checkpoint inhibitor (ICI) therapy. This study will compare the usual care treatment of single fraction stereotactic radiosurgery (SSRS) given on one day versus fractionated stereotactic radiosurgery (FSRS), which is a lower dose of radiation given over a few days to determine if FSRS is better or worse at reducing side effects than usual care treatment.
Recruiting1 award N/A
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Atrium Health Cabarrus/LCI-Concord?
Atrium Health Cabarrus/LCI-Concord is a medical facility located in Concord, North Carolina. This center is recognized for care of Cancer, Breast Cancer, Adenocarcinoma, Recurrence, Lung Cancer and other specialties. Atrium Health Cabarrus/LCI-Concord is involved with conducting 87 clinical trials across 165 conditions. There are 13 research doctors associated with this hospital, such as Nilanjan Ghosh, Earle Burgess, MD, Daniel R. Carrizosa, and John H. Heinzerling.